Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna™ Appoints Patrick Gray to Board of Directors to Support Continued Growth
Company Announces Retirement of Board of Director Veteran Dennis Langer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 19, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML
Toggle Summary Dicerna™ to Present at H.C. Wainwright 21st Annual Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive...
View HTML
Toggle Summary Dicerna™ Reports Second Quarter 2019 Financial Results and Provides Corporate Update
— Strengthened Management with Senior Hires Across Medical Affairs, Commercial, Regulatory, and Patient Advocacy and Patient Services — — Initiated dosing in PHYOX™3 Roll-over Extension Study for the Treatment of Primary Hyperoxaluria (PH) — — Received Breakthrough Therapy Designation for DCR-PHXC...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML
Toggle Summary Dicerna™ to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2019 financial...
View HTML
Toggle Summary Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 (PH1)
—Designation Follows Recently Reported PHYOX™1 Phase 1 Data Showing Positive Clinical Responses to DCR-PHXC— —FDA Recognizes Primary Hyperoxaluria Types 2 and 3 (PH2 and PH3) as Meeting Criteria for a Serious or Life-Threatening Disease or Condition— CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul....
View HTML
Toggle Summary Dicerna™ to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
— Company Submitted Clinical Trial Application and Plans to Initiate Multicenter Phase 1/2 Trial in Third Quarter of 2019 — — Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Program Broadens Dicerna’s Commitment to Addressing Chronic Liver Diseases— CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul....
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 1, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the...
View HTML
Toggle Summary Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
—Researchers Report Substantial Oxalate Reduction Following Single-Dose Administration of DCR-PHXC in Additional Patients with PH2— —Enrollment Underway in Pivotal PHYOX2 Trial of DCR-PHXC— CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 21, 2019-- Dicerna TM Pharmaceuticals, Inc....
View HTML